Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that 17p deletion status confers therapeutic sensitivity to Ibrutinib in patients with Chronic Lymphocytic Leukemia.
The U.S. Food and Drug Administration (FDA) granted approval to ibrutinib for the treatment of adult patients with chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL) with a 17p deletion.
This statement is based on a regulatory approval from the Food and Drug Administration:
IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL) with 17p deletion.